No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Alx Oncology Shares Down in Pre-market as Jefferies Downgrades Stock to 'Hold'
Express News | ALX Oncology Holdings Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $2 From $12
Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdingsto Overweight
ALX Oncology to Present Updated Results From Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients With HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
ALX Oncology Holdings Analyst Ratings